antibioticsАнтибиотики и ХимиотерапияAntibiot Khimioter = Antibiotics and Chemotherapy0235-2990ООО «Издательство ОКИ»10.37489/0235-2990-2022-67-3-4-53-69antibiotics-914Research ArticleОБЗОРЫREVIEWSГеморрагические лихорадки: противовирусные эффекты и молекулярные мишени биологически активных полисахаридов и лектинов из морских гидробионтовHemorrhagic Fevers: Antiviral Effects and Molecular Targets of Biologically Active Polysaccharides and Lectins from Marine Aquatic Organismshttps://orcid.org/0000-0002-2760-9778БеседноваН. Н.BesednovaN. N.

 Беседнова Наталия Николаевна — д. м. н., профессор,академик РАН, главный научный сотрудник лабораториииммунологии

eLIBRARY SPIN-код: 8931-9002. Scopus Author ID: 7006805123 

ул. Сельская, д. 1, г. Владивосток, 690087

 Natalia N. Besednova — D. Sc. in medicine, Professor, Academician of the Russian Academy of Sciences

Vladivostok

eLIBRARY SPIN: 8931-9002. Scopus Author ID: 7006805123 

besednoff_lev@mail.ruhttps://orcid.org/0000-0002-2760-9778ЗапорожецТ. С.ZaporozhetsT. S.

 Запорожец Татьяна Станиславовна — д. м. н., главныйнаучный сотрудник лаборатории иммунологии

ResearcherID: Y-9425-2018. eLIBRARY SPIN-код: 8931-9002. Scopus Author ID: 7006805123 

ул. Сельская, д. 1, г. Владивосток, 690087

 Tatyana S. Zaporozhets — D. Sc. in medicine

ResearcherID: Y-9425-2018. eLIBRARY SPIN: 8931-9002. Scopus Author ID: 7006805123 

https://orcid.org/0000-0003-4456-808XАндрюковБ. Г.AndryukovB. G.

 Андрюков Борис Георгиевич — д. м. н, ведущий научныйсотрудник лаборатории молекулярной микробиологии

ResearcherID: J-3752-2018. eLIBRARYSPIN-код: 7757-3838. Scopus Author ID: 57191370698 

ул. Сельская, д. 1, г. Владивосток, 690087

 Boris G. Andryukov — D. Sc. in medicine

ResearcherID: J-3752-2018. eLIBRARY SPIN:7757-3838. Scopus Author ID: 57191370698 

ЕрмаковаС. П.ErmakovaS. P.

 Ермакова Светлана Павловна — д. х. н., главный научныйсотрудник лаборатории химии ферментов

 Владивосток 

 Svetlana P. Ermakova — D. Sc. in chemistry

Vladivostok 

https://orcid.org/0000-0002-4315-6959КузнецоваТ. А.KuznetsovaT. A.

 Кузнецова Татьяна Алексеевна — д. м. н., главный научный сотрудник лаборатории иммунологии

ResearcherID: I-8399-2018. eLIBRARY SPIN-код: 2359-1132. Scopus Author ID: 7202571979 

ул. Сельская, д. 1, г. Владивосток, 690087

 Tatyana A. Kuznetsova — D. Sc. in medicine

ResearcherID: I-8399-2018. eLIBRARY SPIN: 2359-1132. Scopus Author ID: 7202571979 

КрыжановскийС. П.KryzhanovskyS. P.

 Крыжановский Сергей Петрович — д. м. н., ученый секретарь

Владивосток 

 Sergey P. Kryzhanovsky — D. Sc. in medicine

Vladivostok 

https://orcid.org/0000-0001-8610-7623ЩелкановМ. Ю.ShchelkanovM. Yu.

 Щелканов Михаил Юрьевич — д. б. н., директор; заведующий лабораторией вирусологии,  ведущий научный сотрудник

ResearcherID: L-6164-2016. eLIBRARY SPIN-код: 5736-7230. Scopus Author ID: 7004251692 

ул. Сельская, д. 1, г. Владивосток, 690087

 Mikhail Yu. Shchelkanov — D. Sc. in biology

Researcher ID: L-6164-2016. eLIBRARY SPIN: 5736-7230. Scopus Author ID: 7004251692 

ФГБНУ «Научно-исследовательский институт эпидемиологии и микробиологии им. Г. П. Сомова» РоспотребнадзораРоссияG. P. Somov Research Institute of Epidemiology and Microbiology by Federal Service for Surveillance on Consumer Rights Protection and Human WellbeingRussian FederationТихоокеанский институт биоорганической химии им. Г. Б. Елякова ДВО РАНРоссияG.B. Elyakov Pacific Institute of Bioorganic Chemistry, Far Eastern Branch of Russian Academy of SciencesRussian FederationМедицинское объединение ДВО РАНРоссияMedical Association of the Far Eastern Branch of the Russian Academy of SciencesRussian FederationФГБНУ «Научно-исследовательский институт эпидемиологии и микробиологии им. Г. П. Сомова» Роспотребнадзора; ФГБУН «Федеральный научный Центр биоразнообразия наземной биоты Восточной Азии» ДВО РАНРоссияFederal Scientific Center of the Eastern Asia Terrestrial Biodiversity, Far Eastern Branch of Russian Academy of Sciences; G. P. Somov Research Institute of Epidemiology and Microbiology by Federal Service for Surveillance on Consumer Rights Protection and Human WellbeingRussian Federation202205082022673-45369Copyright © ООО «Издательство ОКИ», 20222022ООО «Издательство ОКИ»ООО «Издательство ОКИ»https://www.antibiotics-chemotherapy.ru/jour/about/submissions#copyrightNoticehttps://www.antibiotics-chemotherapy.ru/jour/article/view/914

Поиск и создание этиотропных препаратов является одной из важнейших задач современной вирусолологии. В настоящем обзоре рассматриваются противовирусные эффекты некоторых природных веществ (сульфатированных полисахаридов и лектинов из морских гидробионтов) по отношению к возбудителям геморрагических лихорадок. Такие соединения могут быть альтернативой синтетическим лекарствам благодаря низкой токсичности, редким побочным эффектам и отсутствию формирования к ним резистентности у вирусов. Кроме сильного противовирусного действия полисахариды и лектины обладают противовоспалительными, иммуномодулирующими, антиоксидантными и антитоксическими свойствами, что является важным для купирования многочисленных нарушений в организме, обусловленных возбудителями вирусных геморрагических лихорадок. В заключительной части обзора рассматриваются перспективы использования этих соединений как основы для создания новых лекарственных препаратов и биологически активных добавок к пище на их основе.

The search and creation of etiotropic drugs is one of the most important tasks of modern virology. This review examines the antiviral influence of certain natural substances (sulfated polysaccharides and lectins from marine hydrobionts) on the causative agents of hemorrhagic fevers. Such compounds can be used as an alternative to synthetic drugs due to their low toxicity, rare side effects, and the absence of virus resistance. In addition to a strong antiviral effect, polysaccharides and lectins possess anti-inflammatory, immunomodulatory, antioxidant, and antitoxic properties, which are important for the relief of numerous disorders caused by the pathogens of viral hemorrhagic fevers. The prospects of using these compounds as the basis for the creation of new drugs and biologically active food additives are considered in the final part of the review.

вирусные геморрагические лихорадкиморские гидробионтысульфатированные полисахаридылектиныперспективы использованияviral hemorrhagic feversmarine hydrobiontssulfated polysaccharideslectinsprospects for useReferencesАристова В.А., Колобухина Л.В., Щелканов М.Ю., Львов Д.К. Дифференциация генетических вариантов вирусов Крымской-Конго геморрагической лихорадки. Вопросы вирусологии. 2011; 46 (4): 7–15.Aristova V.A., Kolobukhina L.V., Shchelkanov M.Jyu., L'vov D.K. Differentsiatsiya geneticheskikh variantov virusov Krymskoj-Kongo gemorragicheskoj likhoradki. Voprosy Virusologii. 2011; 46 (4): 7–15. (in Russian)]Joniec J., Kolodziej M., Bartoszcze M. et al. Res. On prevention and treatment of hemorrhagic fever. Ann Agric Environ Med. 2012; 19 (2): 165–171.Joniec J., Kolodziej M., Bartoszcze M. et al. Res. On prevention and treatment of hemorrhagic fever. Ann Agric Environ Med. 2012; 19 (2): 165–171.Lvov D.K., Shchelkanov M.Yu., Alkhovsky S.V., Deryabin P.G. Zoonotic viruses of Northern Eurasia. Taxonomy and Ecology. Academic Press, 2015; 452.Lvov D.K., Shchelkanov M.Yu., Alkhovsky S.V., Deryabin P.G. Zoonotic viruses of Northern Eurasia. Taxonomy and Ecology. Academic Press, 2015; 452.Щелканов М.Ю., Дедков В.Г., Галкина И.В. и др. Районирование африканской природноочаговой провинции в отношении филовирусных лихорадок. Вестник РАМН. 2017; 72 (5): 325–335. doi.org/10.15690/vramn804.Shchelkanov M.Jyu., Dedkov V.G., Galkina I.V. i dr. Rajonirovanie afrikanskoj prirodnoochagovoj provintsii v otnoshenii filovirusnykh likhoradok. Vestnik RAMN. 2017; 72 (5): 325–335. doi.org/10.15690/vramn804. (in Russian)]Руководство по вирусологии: вирусы и вирусные инфекции человека и животных. Под ред. Д.К.Львова; М.: Медицинское информационное агентство, 2013; 1197. [Rukovodstvo po virusologii: virusy i virusnye infektsii cheloveka i zhivotnykh. Pod red. D.K.L'vova; Moscow: Meditsinskoe Informatsionnoe Agentstvo, 2013; 1197. (in Russian)]Rukovodstvo po virusologii: virusy i virusnye infektsii cheloveka i zhivotnykh. Pod red. D.K.L'vova; Moscow: Meditsinskoe Informatsionnoe Agentstvo, 2013; 1197. (in Russian)]Anishchenko M., Щелканов М.Ю., Алексеев В.В. и др. Молекулярные маркеры патогенности вируса Западного Нила. Вопросы вирусологии. 2010; 55 (1): 4–10.Anishchenko M., Shchelkanov M.Jyu., Alekseev V.V. i dr. Molekulyarnye markery patogennosti virusa Zapadnogo Nila. Voprosy Virusologii. 2010; 55 (1): 4–10. (in Russian)]Щелканов М.Ю., Магассуба Н., Дедков В.Г. и др. Природный резервуар филовирусов и типы связанных с ними эпидемических вспышек на территории Африки. Вестник РАМН. 2017; 72 (2): 112–119. doi: 10.15690/vramn803.Shchelkanov M.Jyu., Magassuba N., Dedkov V.G. i dr. Prirodnyj rezervuar filovirusov i tipy svyazannykh s nimi epidemicheskikh vspyshek na territorii Afriki. Vestnik RAMN. 2017; 72 (2): 112–119. doi: 10.15690/vramn803. (in Russian)]Mariappan V., Pratheesh P., Shanmugam L. et al. Viral hemorrhagic fever: molecular phatogenesisi and current trends of disease management — an update. Current Research in Virological Science. 2021; 2: 100009. doi: 10.1016/j.crivro.2021.100009Mariappan V., Pratheesh P., Shanmugam L. et al. Viral hemorrhagic fever: molecular phatogenesisi and current trends of disease management — an update. Current Research in Virological Science. 2021; 2: 100009. doi: 10.1016/j.crivro.2021.100009Lvov D.K., Butenko A.M., Gromashevsky V.L. et al. West Nile and other emerging-reemerging viruses in Russia. NATO Science Series. Series I. Life and Behavior Sciences. Emerging Biological Threat. V. 370. Amsterdam: IOS Press, 2005; 33–42.Lvov D.K., Butenko A.M., Gromashevsky V.L. et al. West Nile and other emerging-reemerging viruses in Russia. NATO Science Series. Series I. Life and Behavior Sciences. Emerging Biological Threat. V. 370. Amsterdam: IOS Press, 2005; 33–42.Онищенко Г.Г., Топорков В.В., Карнаухов И.Г., Удовиченко С.К. Эпидемия лихорадки Эбола в Западной Африке как чрезвычайная ситуация в области биологической безопасности международного значения. Инфекционные болезни. Новости. Мнения. Обучение. 2016; 1: 61–72.Onishchenko G.G., Toporkov V.V., Karnaukhov I.G., Udovichenko S.K. Epidemiya likhoradki Ebola v Zapadnoj Afrike kak chrezvychajnaya situatsiya v oblasti biologicheskoj bezopasnosti mezhdunarodnogo znacheniya. Infektsionnye bolezni. Novosti. Mneniya. Obuchenie. 2016; 1: 61–72. (in Russian)]Parvez M.K., Parveen S. Evolution and emergence of pathogenic viruses: past, present and future. Intervirology. 2017; 60: 1–7. doi: 10.1159/000478729.Parvez M.K., Parveen S. Evolution and emergence of pathogenic viruses: past, present and future. Intervirology. 2017; 60: 1–7. doi: 10.1159/000478729.Львов Д.Н., Щелканов М.Ю., Джаркенов А.Ф. и др. Популяционные взаимодействия вируса Западного Нила (Flaviviridae, Flavivirus) с членистоногими переносчиками и позвоночными животными в среднем и нижнем поясах дельты Волги (2001–2006 гг.) Вопросы вирусологии. 2009; 2: 36–43.L'vov D.N., Shchelkanov M.Jyu., Dzharkenov A.F. i dr. Populyatsionnye vzaimodejstviya virusa Zapadnogo Nila (Flaviviridae, Flavivirus) s chlenistonogimi perenoschikami i pozvonochnymi zhivotnymi v srednem i nizhnem poyasakh del'ty Volgi (2001–2006 gg.) Voprosy Virusologii. 2009; 2: 36–43. (in Russian)]Sikkema R.S., Koopmans M.P.G. Preparing for emerging zoonotic viruses. Encyclopedia of Virology. 2021: 256–266. doi: 10.1016/B978-0-12-814515-9.00150-8.Sikkema R.S., Koopmans M.P.G. Preparing for emerging zoonotic viruses. Encyclopedia of Virology. 2021: 256–266. doi: 10.1016/B978-0-12-814515-9.00150-8.Hassel J.M., Begon M., Ward M.J., Fevre E.M. Urbanization and disease emergence: dynamics at the wildlife-livestock-human interface. Trends Ecol Evol. 2017; 32: 55–67. doi: 10.16/j.tree.2016.09.012Hassel J.M., Begon M., Ward M.J., Fevre E.M. Urbanization and disease emergence: dynamics at the wildlife-livestock-human interface. Trends Ecol Evol. 2017; 32: 55–67. doi: 10.16/j.tree.2016.09.012Терновой В. А., Щелканов М. Ю., Шестопалов А. М. и др. Выявление вируса Западного Нила в птицах на территории Барабинской и Кулундинской низменностей (Западно-Сибирский пролетный путь) в летне-осенний период 2002 г. Вопросы вирусологии 2004; 49 (3): 52–56.Ternovoj V. A., Shchelkanov M. Jyu., Shestopalov A. M. i dr. Vyyavlenie virusa Zapadnogo Nila v ptitsakh na territorii Barabinskoj i Kulundinskoj nizmennostej (Zapadno-Sibirskij proletnyj put') v letne-osennij period 2002 g. Voprosy Virusologii 2004; 49 (3): 52–56. (in Russian)]Львов Д. К., Щелканов М. Ю., Колобухина Л. В. и др. Серологический мониторинг арбовирусных инфекций в дельте р. Кубань (данные 2006—2007 гг.) Вопросы вирусологии. 2008; 53 (4): 30–35.L'vov D. K., Shchelkanov M. Jyu., Kolobukhina L. V. i dr. Serologicheskij monitoring arbovirusnykh infektsij v del'te r. Kuban' (dannye 2006–2007 gg.) Voprosy Virusologii. 2008; 53 (4): 30–35. (in Russian)]Mirsaedi M., Motahari H., Khamesi M.T. et al. Climate change and respiratory infections. Ann Am Thorac Soc. 2016; 13: 1223–1230. doi: 10.1513/Annals ATS.201511-729PS. doi: 10.1513/AnnalsATS.201511-729PS.Mirsaedi M., Motahari H., Khamesi M.T. et al. Climate change and respiratory infections. Ann Am Thorac Soc. 2016; 13: 1223–1230. doi: 10.1513/Annals ATS.201511-729PS. doi: 10.1513/AnnalsATS.201511-729PS.Щелканов М.Ю., Zoumanigui N., Boiro M.Y., Малеев В.В. Пять мифов о лихорадке Эбола: где кончается вымысел? РМЖ Медицинское обозрение. 2015; 2: 58–66.Shchelkanov M.Jyu., Zoumanigui N., Boiro M.Y., Maleev V.V. Pyat' mifov o likhoradke Ebola: gde konchaetsya vymysel? Russkij Meditsinskij Zhurnal. Meditsinskoe Obozrenie. 2015; 2: 58–66. (in Russian)]Rijal P., Elias S.C., Machado S.R. et al. Therapeutic monoclonal antibodies for Ebola virus infection derived from vaccinated humans. Cell. Reports. 2019; 27(1):172-186.e7. doi: 10.1016/j.celrep.2019.03.020.Rijal P., Elias S.C., Machado S.R. et al. Therapeutic monoclonal antibodies for Ebola virus infection derived from vaccinated humans. Cell. Reports. 2019; 27(1):172-186.e7. doi: 10.1016/j.celrep.2019.03.020.Щелканов М.Ю., Magassouba N.F., Boiro M.Y., Малеев В.В. Причины развития эпидемии лихорадки Эбола в Западной Африке. Lvrach. 2014; (11): 30–36. http://www.lvrach.ru/2014/11/15436092/Shchelkanov M.Jyu., Zoumanigui N., Boiro M.Y., Maleev V.V. Pyat' mifov o likhoradke Ebola: gde konchaetsya vymysel? RMZh Meditsinskoe obozrenie. 2015; 2: 58–66. http://www.lvrach.ru/2014/11/15436092/ (in Russian)]Liu J., Pei T., Mu J. et al. Systems pharmacology uncovers the multiple mechanisms of Xijiao Dihuang Decoction for the treatment of viral hemorrhagic fever. Res. Article. 2016; 2016: 9025036. doi: 10/1155/2016/ 9025036.Liu J., Pei T., Mu J. et al. Systems pharmacology uncovers the multiple mechanisms of Xijiao Dihuang Decoction for the treatment of viral hemorrhagic fever. Res. Article. 2016; 2016: 9025036. doi: 10/1155/2016/ 9025036.Reis J.G., Cadamuro R.D., Cabral A.C. et al. Broad spectrum algae compounds against viruses. Front Microbiol. 2022; 12: 809296. doi: 10.3389/fmicb.2021.809296.Reis J.G., Cadamuro R.D., Cabral A.C. et al. Broad spectrum algae compounds against viruses. Front Microbiol. 2022; 12: 809296. doi: 10.3389/fmicb.2021.809296.Alam M. A., Parra-Saldivar R., Bilal M. et al. Algae-derived bioactive molecules for the potential treatment of SARS-CoV-2. Molecules. 2021; 26: 2134. doi: 10.3390/molecules26082134.Alam M. A., Parra-Saldivar R., Bilal M. et al. Algae-derived bioactive molecules for the potential treatment of SARS-CoV-2. Molecules. 2021; 26: 2134. doi: 10.3390/molecules26082134.Reinolds D., Huesemann M., Edmundson S. et al. Viral inhibitors derived from macroalgae, microalgae and cyanobacteria: a reviw of antiviral throughout pathogenesis. Algal Res. 2021; 57: 102331. doi: 10.1016/j.algal.2021.102331.Reinolds D., Huesemann M., Edmundson S. et al. Viral inhibitors derived from macroalgae, microalgae and cyanobacteria: a reviw of antiviral throughout pathogenesis. Algal Res. 2021; 57: 102331. doi: 10.1016/j.algal.2021.102331.Hammed I., Ozogul F., Ozogul Y., Regenstein J.M. Marine bioactive compounds and their health benefits: a review. Compr Rev Food Sci. 2015; 14: 446–465. doi: 10.1111/1541-4337.12136.Hammed I., Ozogul F., Ozogul Y., Regenstein J.M. Marine bioactive compounds and their health benefits: a review. Compr Rev Food Sci. 2015; 14: 446–465. doi: 10.1111/1541-4337.12136.Zhong H., Gao X., Cheng C. et al. The structural characteristics of seaweed polysaccharides and their application in gel drug delivery systems. Mar Drugs. 2020; 18: 658. doi: 10.3390/md18120658.Zhong H., Gao X., Cheng C. et al. The structural characteristics of seaweed polysaccharides and their application in gel drug delivery systems. Mar Drugs. 2020; 18: 658. doi: 10.3390/md18120658.Valcarcel J., Novoa-Carballal R., Perez-Martin R.I. et al. Glycosaminoglycans from marine sources as therapeutic agents. Biotechnology Advances. 2017; 35 (1): 711–725. doi: 10.1016/j.biotechadv.2017.07.008.Valcarcel J., Novoa-Carballal R., Perez-Martin R.I. et al. Glycosaminoglycans from marine sources as therapeutic agents. Biotechnology Advances. 2017; 35 (1): 711–725. doi: 10.1016/j.biotechadv.2017.07.008.Arima K., Fujita H., Toita R. et al. Amounts and compositional analysis of glycosaminoglycans in the tissue of fish. Carbohydrate Res. 2013; 336:25–32. doi: 10.1016/j.carres.2012.11.010.Arima K., Fujita H., Toita R. et al. Amounts and compositional analysis of glycosaminoglycans in the tissue of fish. Carbohydrate Res. 2013; 336:25–32. doi: 10.1016/j.carres.2012.11.010.Zahra Z., Choo D.H., Lee H., Parveen A. Cyanobacteria: review of current potentials and applications. Environments. 2020; 7 (2): 13. doi:10.3390/environments7020013Zahra Z., Choo D.H., Lee H., Parveen A. Cyanobacteria: review of current potentials and applications. Environments. 2020; 7 (2): 13. doi:10.3390/environments7020013Nandagopal P., Steven A.N., Chan L-W. et al. Bioactive metabolites produced by cyanobacteria for growth adaptation and their pharmacological properties. Biology. 2021; 10 (10): 1061. doi: 10.3390/biology10101061.Nandagopal P., Steven A.N., Chan L-W. et al. Bioactive metabolites produced by cyanobacteria for growth adaptation and their pharmacological properties. Biology. 2021; 10 (10): 1061. doi: 10.3390/biology10101061.Wang W., Wang S-X., Guan H.-S. The antiviral activities and mechanisms of marine polysaccharides: an overview. Mar Drugs. 2012; 10 (12): 2795–2816. doi: 10.3390/md10122795.Wang W., Wang S-X., Guan H.-S. The antiviral activities and mechanisms of marine polysaccharides: an overview. Mar Drugs. 2012; 10 (12): 2795–2816. doi: 10.3390/md10122795.Alvarez-Vinas M., Souto S., Florez-Fernandez N. et al. Antiviral activity of carrageenans and processing implications. Mar Drugs. 2021; 19: 437. doi: 10.3390/md19080437.Alvarez-Vinas M., Souto S., Florez-Fernandez N. et al. Antiviral activity of carrageenans and processing implications. Mar Drugs. 2021; 19: 437. doi: 10.3390/md19080437.Asker M.S., Kady E.M., Mahmoud M.G. New trends of the polysaccharides as a drug. World J Agr Soil Sci. 2019; 3 (5): 000572. doi: 10.33552/WJASS.2019.Asker M.S., Kady E.M., Mahmoud M.G. New trends of the polysaccharides as a drug. World J Agr Soil Sci. 2019; 3 (5): 000572. doi: 10.33552/WJASS.2019.Shi D., Sheng A., Chi L. Glycosaminoglycan-protein interactions and their roles in human disease. Front Mol Biosci. 2021 Mar 9; 8: 639666. doi: 10.3389/fmolb.2021]Shi D., Sheng A., Chi L. Glycosaminoglycan-protein interactions and their roles in human disease. Front Mol Biosci. 2021 Mar 9; 8: 639666. doi: 10.3389/fmolb.2021]Hans N., Malik A., Naik S. Antiviral activity of sulfated polysaccharides from marine algae and its application in combating combating COVID-19: mini review. Bioresour. Technol Rep. 2021; 13: 100623. doi:10.1016/j.biteb.2020.100623.Hans N., Malik A., Naik S. Antiviral activity of sulfated polysaccharides from marine algae and its application in combating combating COVID-19: mini review. Bioresour. Technol Rep. 2021; 13: 100623. doi:10.1016/j.biteb.2020.100623.Claus-Desbonnet H., Nikly E., Nalbantova V. et al. Polysaccharides and their derivates as potential antiviral molecules. Viruses. 2022; 14: 426. doi: 10.3390/v14020426.Claus-Desbonnet H., Nikly E., Nalbantova V. et al. Polysaccharides and their derivates as potential antiviral molecules. Viruses. 2022; 14: 426. doi: 10.3390/v14020426.Allen M.M.F., Schols D. Dengue virus entry as target for antiviral therapy. J Trop Med. 2012; 628475. doi: 10.1155/2012/628475.Allen M.M.F., Schols D. Dengue virus entry as target for antiviral therapy. J Trop Med. 2012; 628475. doi: 10.1155/2012/628475.Rodrigues J.A.G., Eloy Y.R.G., Oliveira E. de Sousa et al. An anti-dengue and antiherpetic polysulfated fraction isolated from the green seaweed Caulerpa cupressoides inhibits thrombin generation in vitro. Acta Scientiarum. Biological Sciences. 2017; 3 (2): 149–159. doi: 10.4025actascibiolsci.v3912.28081.Rodrigues J.A.G., Eloy Y.R.G., Oliveira E. de Sousa et al. An anti-dengue and antiherpetic polysulfated fraction isolated from the green seaweed Caulerpa cupressoides inhibits thrombin generation in vitro. Acta Scientiarum. Biological Sciences. 2017; 3 (2): 149–159. doi: 10.4025actascibiolsci.v3912.28081.Kim S.Y., Li B., Linhardt R.J. Pathogenesis and inhibition of flaviviruses from a carbohydrate perspective. Pharmaceuticals. 2017; 10 (2): 44. doi: 10.3390/ph10020044.Kim S.Y., Li B., Linhardt R.J. Pathogenesis and inhibition of flaviviruses from a carbohydrate perspective. Pharmaceuticals. 2017; 10 (2): 44. doi: 10.3390/ph10020044.Fernandez-Romero J.A., Paglini M.G., Priano C. et al. Algal and cyanobacterial lectins and their antimicrobial properties. Mar Drugs. 2021; 19: 687. doi: 10.3390/md19120687.Fernandez-Romero J.A., Paglini M.G., Priano C. et al. Algal and cyanobacterial lectins and their antimicrobial properties. Mar Drugs. 2021; 19: 687. doi: 10.3390/md19120687.Huskens D., Schols D. Algal lectins as potential HIV microbicide candidates. Mar. Drugs. 2012; 10: 1476–1497. doi: 10.3390/md10071476.Huskens D., Schols D. Algal lectins as potential HIV microbicide candidates. Mar. Drugs. 2012; 10: 1476–1497. doi: 10.3390/md10071476.Singh R.S., Walia A.K. Lectins from red algae and their biomedical potential. J Appl Phycol. 2018; 30: 1833–1858. doi: 10.1007/s10811-017-1338-5.Singh R.S., Walia A.K. Lectins from red algae and their biomedical potential. J Appl Phycol. 2018; 30: 1833–1858. doi: 10.1007/s10811-017-1338-5.Abel J., Romero J.A.F., Pagglini M.Q. et al. Algal and cyanobacterial lectins and their antimicrobial properties. Mar Drugs. 2021; 19: 687. doi:10.3390/md19120687.Abel J., Romero J.A.F., Pagglini M.Q. et al. Algal and cyanobacterial lectins and their antimicrobial properties. Mar Drugs. 2021; 19: 687. doi:10.3390/md19120687.Mitchell C.A., Ramessar K., O’Keefe B.R. Antiviral lectins: selective inhibitors of viral entry. Antiviral Res. 2017; 142: 37–54. doi:10.1016/j.antiviral.2017.03.007.Mitchell C.A., Ramessar K., O’Keefe B.R. Antiviral lectins: selective inhibitors of viral entry. Antiviral Res. 2017; 142: 37–54. doi:10.1016/j.antiviral.2017.03.007.Barre A., Simplicien M., Benoist H. et al. Mannose-specific lectins from marine algae: diverse structural scaffolds associated to common virucidal and anti-cancer properties. Mar Drugs. 2019; 17 (8): 440. doi: 10.3390/md17080440.Barre A., Simplicien M., Benoist H. et al. Mannose-specific lectins from marine algae: diverse structural scaffolds associated to common virucidal and anti-cancer properties. Mar Drugs. 2019; 17 (8): 440. doi: 10.3390/md17080440.Romero F.J.A., Paglini M.G., Priano C. et al. Algal and сyanobacterial lectins and their antimicrobial properties. Mar Drugs. 2021; 19: 687; doi:10.3390/md19120687.Romero F.J.A., Paglini M.G., Priano C. et al. Algal and сyanobacterial lectins and their antimicrobial properties. Mar Drugs. 2021; 19: 687; doi:10.3390/md19120687.Barton C., Kouocam J.C., Lasnik A.B. et al. Activity of and effect of subcutaneous treatment with the broad-spectrum antiviral lectin griffitsin in two laboratory rodent models. Antimicrob Agents Chemother. 2014; 58 (1): 120–127. doi: 10.1128/AAC.01407-13.Barton C., Kouocam J.C., Lasnik A.B. et al. Activity of and effect of subcutaneous treatment with the broad-spectrum antiviral lectin griffitsin in two laboratory rodent models. Antimicrob Agents Chemother. 2014; 58 (1): 120–127. doi: 10.1128/AAC.01407-13.Lusvarghi S., Bewley C. Griffitsin: an antiviral lectin with outstanding therapeutic potential. Viruses. 2016; 8 (10): 296. doi: 10.3390/v8100296.Lusvarghi S., Bewley C. Griffitsin: an antiviral lectin with outstanding therapeutic potential. Viruses. 2016; 8 (10): 296. doi: 10.3390/v8100296.Lee C. Griffitsin, a highly potent broad-spectrum antiviral lectin from red algae: from discovery to clinical application. Mar Drugs. 2019; 17 (10): 567. doi: 10.3390/md17100567.Lee C. Griffitsin, a highly potent broad-spectrum antiviral lectin from red algae: from discovery to clinical application. Mar Drugs. 2019; 17 (10): 567. doi: 10.3390/md17100567.Singh R.S., Thakur S.R., Bansal P. Algal lectins as promising biomolecules for biomedical research. Crit Rev Microbiol. 2013; 1–12. Early online4.Singh R.S., Thakur S.R., Bansal P. Algal lectins as promising biomolecules for biomedical research. Crit Rev Microbiol. 2013; 1–12. Early online4.Ryu W-S. Molecular virology of human. Pathogenic Viruses. 2017; 31–45. doi: 10.1016/B978-0-12-800838-6.00003-5.Ryu W-S. Molecular virology of human. Pathogenic Viruses. 2017; 31–45. doi: 10.1016/B978-0-12-800838-6.00003-5.Bianculli R.H., Mase J.D., Schulz M.D. Antiviral polymers: past approaches and future possibilities. Macromolecules. 2020; 53: 9158–9186. doi:10.1021/acs.macromol.0c01273.Bianculli R.H., Mase J.D., Schulz M.D. Antiviral polymers: past approaches and future possibilities. Macromolecules. 2020; 53: 9158–9186. doi:10.1021/acs.macromol.0c01273.Bi X., Yi S., Zhang A. et al. Epidemiology of hemorrhagic fever with renal syndrome in Taian area. Sci Rep. 2021; 11 (1): 11596. doi: 10.1038/s41598-021-91029-1.Bi X., Yi S., Zhang A. et al. Epidemiology of hemorrhagic fever with renal syndrome in Taian area. Sci Rep. 2021; 11 (1): 11596. doi: 10.1038/s41598-021-91029-1.Noack D., Goeijenbier M., Reusken C.B.E.M. et al. Orthohantavirus pathogenesis and cell tropism. Front Cell Infect Microbiol. 2020; 10: 399. doi:10.3389/fcimb.2020.00399.Noack D., Goeijenbier M., Reusken C.B.E.M. et al. Orthohantavirus pathogenesis and cell tropism. Front Cell Infect Microbiol. 2020; 10: 399. doi:10.3389/fcimb.2020.00399.Lupusoru G., Lupusoru M., Ailincai I. et al. Hemorrhagic fever with renal syndrome: a pathology in whose diagnosis kidney biopsy plays a major role. Exp Ther Med. 2021; 22 (3): 984. doi.org/10.3892/etm.2021.10416.Lupusoru G., Lupusoru M., Ailincai I. et al. Hemorrhagic fever with renal syndrome: a pathology in whose diagnosis kidney biopsy plays a major role. Exp Ther Med. 2021; 22 (3): 984. doi.org/10.3892/etm.2021.10416.Mir S. Hantavirus induced kidney diseases. Front Med (Lausanne). 2022; 8: 795340. doi: 10.3389/fmed.2021.795340.Mir S. Hantavirus induced kidney diseases. Front Med (Lausanne). 2022; 8: 795340. doi: 10.3389/fmed.2021.795340.Liang W., Gu X., Li X. et al. Mapping the epidemic changes and risks of hemorrhagic fever with renal syndrome in Shaanxi Province, China, 2005–2016. Sci Rep. 2018; 8: 749. doi: 10.1038/s41598-017-18819-4.Liang W., Gu X., Li X. et al. Mapping the epidemic changes and risks of hemorrhagic fever with renal syndrome in Shaanxi Province, China, 2005–2016. Sci Rep. 2018; 8: 749. doi: 10.1038/s41598-017-18819-4.Yashina L.N., Smetannikova N.A., Kushnareva T.V. et al. Hemorrhagic fever with renal syndrome in Vladivostok city, Russia. Front. Publ Health. 2021; 9: 620279. doi: 10.3389/fpubh.2021.620279.Yashina L.N., Smetannikova N.A., Kushnareva T.V. et al. Hemorrhagic fever with renal syndrome in Vladivostok city, Russia. Front. Publ Health. 2021; 9: 620279. doi: 10.3389/fpubh.2021.620279.Иванова А.В., Попов Н.В., Карнаухов И.Г., Чумачкова Е.А. Хантавирусные болезни: обзор эпидемиологической ситуации и эпидемиологических рисков в регионах мира. Проблемы особоопасных инфекций. 2021; 1: 23–31. doi: 10.21055/0370-1069-2021-1-23-31.Ivanova A.V., Popov N.V., Karnaukhov I.G., Chumachkova E.A. Khantavirusnye bolezni: obzor epidemiologicheskoj situatsii i epidemiologicheskikh riskov v regionakh mira. Problemy Osoboopasnykh Infektsij. 2021; 1: 23–31. doi: 10.21055/0370-1069-2021-1-23-31. (in Russian)]Mayor J., Engler O., Rothenberger S. Antiviral efficacy of ribavirin and favipiravir against hantaan virus. Microorganisms. 2021; 9 (6): 1306. doi: 10.3390/microorganisms9061306.Mayor J., Engler O., Rothenberger S. Antiviral efficacy of ribavirin and favipiravir against hantaan virus. Microorganisms. 2021; 9 (6): 1306. doi: 10.3390/microorganisms9061306.Макаренкова И.Д. Молекулярно-клеточные механизмы активации врожденного иммунитета сульфатированными полисахаридами бурых водорослей. Дисс. … докт. мед. наук. М. 2013; 231.Makarenkova I.D. Molekulyarno-kletochnye mekhanizmy aktivatsii vrozhdennogo immuniteta sul'fatirovannymi polisakharidami burykh vodoroslej. Diss. …dokt. med. nauk. Moscow: 2013; 231. (in Russian)Сifuentes-Munoz N., Salazar-Quiroz N., Tishler N.D. Hantavirus Gn and Gc envelope glycoproteins: key structural units for virus cell entry and virus assembly. Viruses. 2014; 6 (4): 1801–1822. doi: 10.3390/v6041801.Сifuentes-Munoz N., Salazar-Quiroz N., Tishler N.D. Hantavirus Gn and Gc envelope glycoproteins: key structural units for virus cell entry and virus assembly. Viruses. 2014; 6 (4): 1801–1822. doi: 10.3390/v6041801.Mittler E., Dieterle M.E., Kleinfelter L.M. et al. Hantavirus entry:perspectives and recent advances. Adv Virus Res. 2019; 104: 185–224. doi:10.1016/bs.aivir.2019.07.002.Mittler E., Dieterle M.E., Kleinfelter L.M. et al. Hantavirus entry:perspectives and recent advances. Adv Virus Res. 2019; 104: 185–224. doi:10.1016/bs.aivir.2019.07.002.Dietele M.E., Sola-Riera C., Ye C. et al. Genetic depletion studies inform receptor usage by virulent hantaviruses in human endothelial cells. eLife. 2021; 10: e69708. doi: 10.7554/eLife.69708.Dietele M.E., Sola-Riera C., Ye C. et al. Genetic depletion studies inform receptor usage by virulent hantaviruses in human endothelial cells. eLife. 2021; 10: e69708. doi: 10.7554/eLife.69708.Krylova N.V., Silchenco A., Pott A.B. et al. In vitro anti-orthohantavirus activity of the high- and low-molecular-weight fractions of fucoidan from the brown alga Fucus evanescens. Mar Drugs. 2021; 19 (10): 577. doi: 10.3390/md19100577.Krylova N.V., Silchenco A., Pott A.B. et al. In vitro anti-orthohantavirus activity of the high- and low-molecular-weight fractions of fucoidan from the brown alga Fucus evanescens. Mar Drugs. 2021; 19 (10): 577. doi: 10.3390/md19100577.Shrivastava-Ranjan P., Lo M.K., Chatterjee P. et al. Hantavirus infection is inhibited by griffitsin in cell culture. Front Cell Infect Microbiol. 2020; 10: 561502. doi: 10.3389/fcimb.2020.561502.Shrivastava-Ranjan P., Lo M.K., Chatterjee P. et al. Hantavirus infection is inhibited by griffitsin in cell culture. Front Cell Infect Microbiol. 2020; 10: 561502. doi: 10.3389/fcimb.2020.561502.Lo Y-L., Liou G-G., Lyu J-H. et al. Dengue virus infection is through a cooperative interaction between a mannose receptor and CLEC5A on macrophage as a multivalent hetero-complex. PLoS ONE. 2016; 11 (11): e0166474. doi: 10.1371/journal.pone.0166474.Lo Y-L., Liou G-G., Lyu J-H. et al. Dengue virus infection is through a cooperative interaction between a mannose receptor and CLEC5A on macrophage as a multivalent hetero-complex. PLoS ONE. 2016; 11 (11): e0166474. doi: 10.1371/journal.pone.0166474.Gomaa H., Elshoubaky G.A. Antiviral activity of sulfated polysaccharides carrageenan from some marine seaweeds. Int J Curr Pharm Rev Res. 2015; 7 (1): 34–42.Gomaa H., Elshoubaky G.A. Antiviral activity of sulfated polysaccharides carrageenan from some marine seaweeds. Int J Curr Pharm Rev Res. 2015; 7 (1): 34–42.Hasan M.J., Tabassum T., Sharif M. et al. Comparison of clinical manifestation of dengue fever in Bangladesh: an observation over a decade. BMC Infect Dis. 2021, 21 (1): 1113. doi: 10.1186/s12879-021-06788-z.Hasan M.J., Tabassum T., Sharif M. et al. Comparison of clinical manifestation of dengue fever in Bangladesh: an observation over a decade. BMC Infect Dis. 2021, 21 (1): 1113. doi: 10.1186/s12879-021-06788-z.Soneja S., Tsarouchi G., Lumbroso D. et al. A review of dengue’s historical and future health risk from a changing climate. Curr Envir Health Rpt. 2021; 8: 245–265. doi: 10.1007/s40572-021-00322-8.Soneja S., Tsarouchi G., Lumbroso D. et al. A review of dengue’s historical and future health risk from a changing climate. Curr Envir Health Rpt. 2021; 8: 245–265. doi: 10.1007/s40572-021-00322-8.Murugesan A., Manoharan M. Emerging and reemerging viral pathogens. Chapter 16 — Denge virus. 2020; 281–359. doi: 10.1016/B978-0-12-819400-3.00016-8.Murugesan A., Manoharan M. Emerging and reemerging viral pathogens. Chapter 16 — Denge virus. 2020; 281–359. doi: 10.1016/B978-0-12-819400-3.00016-8.Cagno V., Tseligka E.D., Jones S.T., Tapparel C. Heparan sulfate proteoglycans and viral attachment:true receptors or adaptation Bias?. Viruses. 2019; 11 (7): 596. doi: 10.3390/v11070596.Cagno V., Tseligka E.D., Jones S.T., Tapparel C. Heparan sulfate proteoglycans and viral attachment:true receptors or adaptation Bias?. Viruses. 2019; 11 (7): 596. doi: 10.3390/v11070596.Liu P., Ridilla M., Patel P. et al. Beyond attachment:roles of DC-SIGN in dengue virus infection. Traffic. 2017; 18 (4): 218–231. doi: 10.1111/tra.12469.Liu P., Ridilla M., Patel P. et al. Beyond attachment:roles of DC-SIGN in dengue virus infection. Traffic. 2017; 18 (4): 218–231. doi: 10.1111/tra.12469.Sung P-S., Chang W.C., Hsieh S-L. CLEC5A: a promiscuous pattern recognition receptor to microbes and beyond. Lectin in Host Defense against Microbial Infections. 2020; 1204: 5773. doi: 10.1007/978-981-15-1580-4_3.Sung P-S., Chang W.C., Hsieh S-L. CLEC5A: a promiscuous pattern recognition receptor to microbes and beyond. Lectin in Host Defense against Microbial Infections. 2020; 1204: 5773. doi: 10.1007/978-981-15-1580-4_3.Songprakhon P., Limjindaporn T., Perng G.C. et al. Human glucose-regulated protein 78 modulates intracellular production and secretion of nonstructural protein 1 of dengue virus. J Gen Virol. 2018; 99 (10): 1391–1406. doi: 10.1099/jgv.0.001134.Songprakhon P., Limjindaporn T., Perng G.C. et al. Human glucose-regulated protein 78 modulates intracellular production and secretion of nonstructural protein 1 of dengue virus. J Gen Virol. 2018; 99 (10): 1391–1406. doi: 10.1099/jgv.0.001134.Aguilar-Briseno J.A., Upasani V., Bram M. et al. TLR2 on blood monocytes senses dengue virus infection and its expression correlates with disease pathogenesis. Nat Commun. 2020; 11: 3177. doi: 10.1038/s41467-020-16849-7.Aguilar-Briseno J.A., Upasani V., Bram M. et al. TLR2 on blood monocytes senses dengue virus infection and its expression correlates with disease pathogenesis. Nat Commun. 2020; 11: 3177. doi: 10.1038/s41467-020-16849-7.Zaitseva E., Yang S.T., Melikov K. et al. Virus ensures its fusion in late endosomes using compartment-specific lipids. PLoS Pathog. 2010; 6 (10):e1001131. doi: 10.1371/journal.ppat.1001131.Zaitseva E., Yang S.T., Melikov K. et al. Virus ensures its fusion in late endosomes using compartment-specific lipids. PLoS Pathog. 2010; 6 (10):e1001131. doi: 10.1371/journal.ppat.1001131.Screaton G., Mongkolsapaya J., Yacoub S., Roberts C. New insight into the immunopathology and control of dengue virus infection. Nat Rev Immunol. 2015; 15 (12): 745–759. doi: 10.1038/nri3916.Screaton G., Mongkolsapaya J., Yacoub S., Roberts C. New insight into the immunopathology and control of dengue virus infection. Nat Rev Immunol. 2015; 15 (12): 745–759. doi: 10.1038/nri3916.Acosta E.G., Bartenschlager R., Baumert T., Schuster C. The quest for host targets to combat dengue virus infections. Curr Opin Virol. 2016; 20:47–54. doi: 10.1016/j.coviro.2016.09.003.Acosta E.G., Bartenschlager R., Baumert T., Schuster C. The quest for host targets to combat dengue virus infections. Curr Opin Virol. 2016; 20:47–54. doi: 10.1016/j.coviro.2016.09.003.Balsitis S.J., Coloma J., Castro G. et al. Tropism of dengue virus in mice and humans defined by viral nonstructural protein 3-specific immunostaining. Am J Trop Med Hyg. 2009; 80 (3): 416–424.Balsitis S.J., Coloma J., Castro G. et al. Tropism of dengue virus in mice and humans defined by viral nonstructural protein 3-specific immunostaining. Am J Trop Med Hyg. 2009; 80 (3): 416–424.Begum F., Das S., Mukherju D. et al. Insight into the tropism of dengue virus in humans. Viruses. 2019; 11 (2): 1136. doi: 10.3390/v11121136.Begum F., Das S., Mukherju D. et al. Insight into the tropism of dengue virus in humans. Viruses. 2019; 11 (2): 1136. doi: 10.3390/v11121136.Roy S.K., Bhattacharjee S. Dengue virus: epidemiology, biology and disease aetiology. Can J Microbiol. 2021; 67 (10): 687–702. doi: 10.1139/cjm-2020-0572.Roy S.K., Bhattacharjee S. Dengue virus: epidemiology, biology and disease aetiology. Can J Microbiol. 2021; 67 (10): 687–702. doi: 10.1139/cjm-2020-0572.Nedjadi T., El-Kafrawy S., Sohrab S.S. et al. Tackling dengue fever: current status and challenges. Virol J. 2015; 12: 212. doi: 10.1186/s12985-015-0444-8.Nedjadi T., El-Kafrawy S., Sohrab S.S. et al. Tackling dengue fever: current status and challenges. Virol J. 2015; 12: 212. doi: 10.1186/s12985-015-0444-8.Lopes J.L., Quinteiro V.S.T., Wouk J. et al. Sulfonated and carboxymethylated β-glucan derivatives with inhibitory activity against Herpes and Dengue viruses. Int J Mol Sci. 2021; 22 (20): 11013. doi: 10.3390/ijms222011013.Lopes J.L., Quinteiro V.S.T., Wouk J. et al. Sulfonated and carboxymethylated β-glucan derivatives with inhibitory activity against Herpes and Dengue viruses. Int J Mol Sci. 2021; 22 (20): 11013. doi: 10.3390/ijms222011013.Koishi A.C., Zanello P.R., Bianco E.M. et al. Screening of Dengue virus antiviral activity of marine seaweeds by an in situ enzyme-linked immunosorbent assay. PLoS ONE. 2012; 7 (12): e51089. doi: 10.1371/journal.pone.0051089Koishi A.C., Zanello P.R., Bianco E.M. et al. Screening of Dengue virus antiviral activity of marine seaweeds by an in situ enzyme-linked immunosorbent assay. PLoS ONE. 2012; 7 (12): e51089. doi: 10.1371/journal.pone.0051089Trost B., Smit J.M. Recent advances in antiviral drug development towards dengue virus. Curr Opin Virol. 2020; 43: 9–21. doi: 10.1016/j.coviro.2020.07.009.Trost B., Smit J.M. Recent advances in antiviral drug development towards dengue virus. Curr Opin Virol. 2020; 43: 9–21. doi: 10.1016/j.coviro.2020.07.009.Talarico L.B., Pujol C.A., Zibetti R.G.M. et al. The antiviral activity of sulfated polysaccharides against dengue virus is dependent on virus serotype and host cell. Antiviral Res. 2005; 66 (2–3): 103–110. doi: 10.1016/j.antiviral.2005.02.001.Talarico L.B., Pujol C.A., Zibetti R.G.M. et al. The antiviral activity of sulfated polysaccharides against dengue virus is dependent on virus serotype and host cell. Antiviral Res. 2005; 66 (2–3): 103–110. doi: 10.1016/j.antiviral.2005.02.001.Talarico L.B., Damonte E.B. Interference in dengue virus adsorbtion and uncoating by carrageenans. Virology. 2007; 363 (2): 473–485. doi: 10.1016/j.virol.2007.01.043.Talarico L.B., Damonte E.B. Interference in dengue virus adsorbtion and uncoating by carrageenans. Virology. 2007; 363 (2): 473–485. doi: 10.1016/j.virol.2007.01.043.Talarico L.B., Noseda M.D., Ducatti D.R.B. et al. Differential inhibition of dengue virus infection in mammalian and mosquito cells by iota-carrageenan. J Gen Virol. 2011; 92: 1332–1342. doi: 10.1099/vir.0028522-0.Talarico L.B., Noseda M.D., Ducatti D.R.B. et al. Differential inhibition of dengue virus infection in mammalian and mosquito cells by iota-carrageenan. J Gen Virol. 2011; 92: 1332–1342. doi: 10.1099/vir.0028522-0.Wikan N., Kuadkitkan A., Smith D.R. The Aedes aegypti cell line CCL125 is dengue virus permissive. J Virol Methods. 2009; 157 (2): 227–230. doi:10.1016/j.jviromet.2008.12.019. Epub 2009 Jan 19.Wikan N., Kuadkitkan A., Smith D.R. The Aedes aegypti cell line CCL125 is dengue virus permissive. J Virol Methods. 2009; 157 (2): 227–230. doi:10.1016/j.jviromet.2008.12.019. Epub 2009 Jan 19.Pujol C.A., Estevez J.M., Carlucci M.J. et al. Novel DL-galactan hybrids from the red seaweed Gymnogongrus torulosus are potent inhibitors of herpes simplex virus and dengue virus. Antivir Chem Chemother. 2002; 13: 83–89. doi: 10.1177/095632020201300202.Pujol C.A., Estevez J.M., Carlucci M.J. et al. Novel DL-galactan hybrids from the red seaweed Gymnogongrus torulosus are potent inhibitors of herpes simplex virus and dengue virus. Antivir Chem Chemother. 2002; 13: 83–89. doi: 10.1177/095632020201300202.Pujol C.A., Ray S., Ray B., Damonte E. Antiviral activity against dengue virus of diverse classes of algal sulfated polysaccharides. Int J Biol Macromol. 2012; 51 (4): 412–416. doi: 10.1016/j.ijbiomac.2012.05.028.Pujol C.A., Ray S., Ray B., Damonte E. Antiviral activity against dengue virus of diverse classes of algal sulfated polysaccharides. Int J Biol Macromol. 2012; 51 (4): 412–416. doi: 10.1016/j.ijbiomac.2012.05.028.Piccini L.E., Carro A.C., Quintana V.M., Damonte E.B. Antibody-independent and dependent infection of human myeloid cells with dengue virus is inhibited by carrageenan. Virus Res. 2020; 290: 198150. doi: 10.1016/j.virusres.2020.198150.Piccini L.E., Carro A.C., Quintana V.M., Damonte E.B. Antibody-independent and dependent infection of human myeloid cells with dengue virus is inhibited by carrageenan. Virus Res. 2020; 290: 198150. doi: 10.1016/j.virusres.2020.198150.Hidari K.I.P.J., Takahashi N., Arihara M. et al. Structure and anti-dengue virus activity of sulfated polysaccharide from a marine alga. Biochem Biophys Res Commun. 2008; 376 (1): 91–95. doi: 10.1016/j.bbrc.2008.08.100Hidari K.I.P.J., Takahashi N., Arihara M. et al. Structure and anti-dengue virus activity of sulfated polysaccharide from a marine alga. Biochem Biophys Res Commun. 2008; 376 (1): 91–95. doi: 10.1016/j.bbrc.2008.08.100Hidari K.I.P., Abe T., Suzuki T. Carbohydrate-related inhibitors of dengue virus entry. Viruses. 2013; 5 (2): 605–618. doi: 10.1177/095632020201300202Hidari K.I.P., Abe T., Suzuki T. Carbohydrate-related inhibitors of dengue virus entry. Viruses. 2013; 5 (2): 605–618. doi: 10.1177/095632020201300202Fuentes P.E.P., Benito J.S.S., Ruiz C.H.M. et al. Actividad anti-dengue in vitro del alga marina Hypnea cervicornis. Rev Mex Cienc Farm. 2017; 48 (1).Fuentes P.E.P., Benito J.S.S., Ruiz C.H.M. et al. Actividad anti-dengue in vitro del alga marina Hypnea cervicornis. Rev Mex Cienc Farm. 2017; 48 (1).Ding L., Ma Y., Huang B., Chen S. Effects of seawater salinity and pigment contents in Hypnea cervicornis. J. Agardh (Gigartinales, Rhodophyta). Biomed Res Int. 2013; 594308. doi:10.1155/2013/594308.Ding L., Ma Y., Huang B., Chen S. Effects of seawater salinity and pigment contents in Hypnea cervicornis. J. Agardh (Gigartinales, Rhodophyta). Biomed Res Int. 2013; 594308. doi:10.1155/2013/594308.Alexandre K.B., Gray E.S., Mufandu H. et al. The lectins griffitsin, cyanovirin-N and scytovirin inhibit HIV-1 binding to the DC-SIGN receptor and transfer to CD4+ cells. Virology. 2012; 423 (2): 175–186. doi:10.1016/j.virol.2011.12.001.Alexandre K.B., Gray E.S., Mufandu H. et al. The lectins griffitsin, cyanovirin-N and scytovirin inhibit HIV-1 binding to the DC-SIGN receptor and transfer to CD4+ cells. Virology. 2012; 423 (2): 175–186. doi:10.1016/j.virol.2011.12.001.Garrison A.R., Giomarelli B.G., Lear-Rooney C.M. et al. The cyanobacterial lectin scytovirin displays potent in vitro and in vivo activity against Zaire Ebola virus. Antivir Res. 2014; 0: 1–7. doi: 10.1016/j.antiviral.2014.09.0123.Garrison A.R., Giomarelli B.G., Lear-Rooney C.M. et al. The cyanobacterial lectin scytovirin displays potent in vitro and in vivo activity against Zaire Ebola virus. Antivir Res. 2014; 0: 1–7. doi: 10.1016/j.antiviral.2014.09.0123.Mazalowska M., Kouokam J.C. Lectins as promising therapeutics for the prevention and treatment of HIV and other potential coinfections. Review article. Open Access. Hindawi BioMed Res Int. 2018; 2018: 3750646. doi: 10.1155/2018/3750646.Mazalowska M., Kouokam J.C. Lectins as promising therapeutics for the prevention and treatment of HIV and other potential coinfections. Review article. Open Access. Hindawi BioMed Res Int. 2018; 2018: 3750646. doi: 10.1155/2018/3750646.Kouokam J.C., Lasnik A.B., Palmer K.E. Studies in a murine model confirm the safety of griffitsin and advocate its further development as a microbicide targeting HIV-1 and other enveloped viruses. Viruses. 2016; 8:311. doi: 10.3390/v8110311.Kouokam J.C., Lasnik A.B., Palmer K.E. Studies in a murine model confirm the safety of griffitsin and advocate its further development as a microbicide targeting HIV-1 and other enveloped viruses. Viruses. 2016; 8:311. doi: 10.3390/v8110311.De Clercq E. Ebola virus(EBOV) infection: therapeutic strategies. Biochem Pharmacol. 2015; 93 (1): 1–10. doi: 10.1016/j.bcp.2014.11.008.De Clercq E. Ebola virus(EBOV) infection: therapeutic strategies. Biochem Pharmacol. 2015; 93 (1): 1–10. doi: 10.1016/j.bcp.2014.11.008.Singh R.S.; Walia A.K. Lectins from red algae and their biomedical potential. J Appl Phycol. 2018, 30: 1833–1858. doi: 10.1007/s10811-017-1338-5.Singh R.S.; Walia A.K. Lectins from red algae and their biomedical potential. J Appl Phycol. 2018, 30: 1833–1858. doi: 10.1007/s10811-017-1338-5.Barrientos L.G., O’Keefe B.R., Bray M., Sanchez A., Gronenborn A.M., Boyd M.R. Cyanovirin-N binds to the viral surface glycoprotein GP1,2 and inhibits infectivity of Ebola virus. Antiviral Res. 2003; 58: 47–56. doi: 10.1016/s0166-3542(02)00183-3.Barrientos L.G., O’Keefe B.R., Bray M., Sanchez A., Gronenborn A.M., Boyd M.R. Cyanovirin-N binds to the viral surface glycoprotein GP1,2 and inhibits infectivity of Ebola virus. Antiviral Res. 2003; 58: 47–56. doi: 10.1016/s0166-3542(02)00183-3.El-Shafei R., Hegazy H., Acharya B. A review of antiviral and antioxidant activity of bioactive metabolite of macroalgae within an optimized extraction method. Energies. 2021; 14: 3092. doi: 10.3390/en14113092.El-Shafei R., Hegazy H., Acharya B. A review of antiviral and antioxidant activity of bioactive metabolite of macroalgae within an optimized extraction method. Energies. 2021; 14: 3092. doi: 10.3390/en14113092.Barrientos L.G., Lasala F., Otero J.R. et al. In vitro evaluation of cyanovirin-N antiviral activity, by use of lentiviral vectors pseudotyped with Filovirus envelope glycoproteins. J Infect Dis. 2004; 189 (8): 1440–1443. doi: 10.1086/382658.Barrientos L.G., Lasala F., Otero J.R. et al. In vitro evaluation of cyanovirin-N antiviral activity, by use of lentiviral vectors pseudotyped with Filovirus envelope glycoproteins. J Infect Dis. 2004; 189 (8): 1440–1443. doi: 10.1086/382658.Liu J., Obaidi I., Nagar S et al. The antiviral potential of algal-derived macromolecules. Curr Res Biotechnol. 2021; 3: 120–134. doi:10.1016/j.crbiot.2021.04.003.Liu J., Obaidi I., Nagar S et al. The antiviral potential of algal-derived macromolecules. Curr Res Biotechnol. 2021; 3: 120–134. doi:10.1016/j.crbiot.2021.04.003.Walia S., Singh M. Tracing plants potential effective against dengue virus: a review. Int J Innovat Res Multidisciplinar Field. 2021; 7 (5): available online on-www.IJIRMF.COM.Walia S., Singh M. Tracing plants potential effective against dengue virus: a review. Int J Innovat Res Multidisciplinar Field. 2021; 7 (5): available online on-www.IJIRMF.COM.Ray B., Ali I., Jana S. et al. Antiviral strategies using natural source-derived sulfated polysaccharides in the light of the COVID-19 pandemic and major human pathogenic viruses. Viruses 2021; 14 (1): 35. doi:10.3390/v14010035.Ray B., Ali I., Jana S. et al. Antiviral strategies using natural source-derived sulfated polysaccharides in the light of the COVID-19 pandemic and major human pathogenic viruses. Viruses 2021; 14 (1): 35. doi:10.3390/v14010035.Pavliga S.N., Kompanets G., Tsygankov V.Y. The experimental research (in vitro) of carrageenans and fucoidans to decrease activity of Hantavirus.Food Environl Virol. 2016; 8: 120–124. doi: 10.1007/s12560-016-9233-9.Pavliga S.N., Kompanets G., Tsygankov V.Y. The experimental research (in vitro) of carrageenans and fucoidans to decrease activity of Hantavirus.Food Environl Virol. 2016; 8: 120–124. doi: 10.1007/s12560-016-9233-9.Salvador B., Sexton N.R., Carrion R. et al. Filoviruses utilize glycosaminoglycans for their attachment to target cells. J Virol. 2013; 87 (6):3295–3304. doi: 10.1128/JVI.01621-12Salvador B., Sexton N.R., Carrion R. et al. Filoviruses utilize glycosaminoglycans for their attachment to target cells. J Virol. 2013; 87 (6):3295–3304. doi: 10.1128/JVI.01621-12

The authors declare that there are no conflicts of interest present.